OXB

"On the FTSE Smallcap index, Oxford Biomedica saw its share price climb to 23.75p, gaining a spectacular 26.67 per cent or 5p. The surge was born of rumours suggesting that Sanofi-Aventis, Oxford Biomedica's partner in the development and commercialisation of TroVax, its cancer treatment drug, may soon mount a bid for the company."

http://www.independent.co.uk/news/business/sharewatch/market-report-taylor-wimpey-knocked-by-bearish-goldman-781103.html